Pluto Bioinformatics

GSE150026: Effects of Tesamorelin on Hepatic Transcriptomic Signatures in HIV-Associated NAFLD

Bulk RNA sequencing

Nonalcoholic fatty liver disease (NAFLD) is a common comorbidity among people living with HIV with a more aggressive course than in the general population. In a recent randomized placebo-controlled trial, we demonstrated that the growth hormone-releasing hormone analogue tesamorelin reduced liver fat and prevented fibrosis progression in HIV-associated NAFLD over one year. In the current study, we leveraged paired liver biopsy specimens from this trial to identify hepatic gene pathways that are differentially modulated by tesamorelin versus placebo to gain key insights into the biological underpinnings of its clinical effects. SOURCE: Steven,K.,GrinspoonMetabolism Massachusetts General Hospital